News|Articles|October 1, 2025

5 Psychiatry Headlines You Missed in September 2025

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

As September 2025 draws to a close, psychiatry research is pushing the field into new territory with innovative therapies and fresh safety insights. A phase 2b trial of MM120 (LSD) showed a single dose could deliver rapid and lasting relief for generalized anxiety disorder, while ammoxetine emerged as a promising antidepressant with fewer adverse events than current standards.